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Abstract 
Background: O6-Methyl-Guanine-Methyl-Transferase (MGMT) silencing by promoter 
methylation may identify cancer patients responding to the alkylating agents dacarbazine 
or temozolomide.  
Patients and methods: We evaluated the prognostic and predictive value of MGMT 
methylation testing both in tumor and cell-free circulating DNA (cfDNA) from plasma 
samples using an ultra-sensitive two-step digital PCR technique (Methyl-BEAMing). 
Results were compared to two established techniques, Methylation specific PCR (MSP) 
and Bs-pyrosequencing. 
Results: Thresholds for MGMT methylated status for each technique were established in 
a training-set of 98 glioblastoma patients. The prognostic and the predictive value of 
MGMT methylated status was validated in a second cohort of 66 glioblastoma patients 
treated with temozolomide in which Methyl-BEAMing displayed a better specificity than the 
other techniques. Cut-off values of MGMT methylation specific for metastatic colorectal 
cancer (mCRC) tissue samples were established in a cohort of 60 patients treated with 
dacarbazine. In mCRC, both quantitative assays Methyl-BEAMing and Bs-pyrosequencing 
outperformed MSP, providing better prediction of treatment response and improvement in 
progression-free survival (PFS)(p<0.001). Ability of Methyl-BEAMing to identify responding 
patients was validated in a cohort of 23 mCRC patients treated with temozolomide and 
pre-selected for MGMT methylated status according to MSP. In mCRC patients treated 
with dacarbazine, exploratory analysis of cfDNA by Methyl-BEAMing showed that MGMT 
methylation was associated with better response and improved median PFS (p=0.008). 
Conclusions: Methyl-BEAMing showed high reproducibility, specificity and sensitivity and 
was applicable to formalin fixed paraffin embedded tissues and cfDNA. This study 
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supports the quantitative assessment of MGMT methylation for clinical purposes since it 
could refine prediction of response to alkylating agents.  
 
Key Words: MGMT; DNA methylation; digital PCR; Metastatic colorectal cancer; 
alkylating agent; cell free circulating DNA. 
 
Key Message: 
Improved assessment of MGMT methylation by a digital PCR method in glioblastoma as 
well as in colorectal cancer samples could be used to identify patients most likely to derive 
clinical benefit from treatment with alkylating agents such as dacarbazine or temozolomide. 
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Introduction 
Alkylating agents such as dacarbazine and temozolomide (TMZ) are currently used in the 
clinical management of lymphomas, melanomas and as first-line treatment for 
glioblastoma (GBM) in addition to surgical resection and radiotherapy. Action of these 
drugs is enhanced in tumors with inactive O6-Methyl-Guanine-Methyl-Transferase 
(MGMT), which is the DNA repair enzyme in charge of removing DNA alkylated adducts 
[1]. Defective MGMT function mainly results from its transcriptional silencing by gene 
promoter methylation. Therefore, MGMT methylation has been proposed as a predictive 
marker of response to alkylating agents [2-5]. Nevertheless, not all patients with MGMT 
hypermethylated tumors respond to treatment with alkylating agents [6, 7]. 
 
MGMT silencing has also been found to occur in several other malignancies [8, 9], 
including colorectal cancer (CRC) [8, 9]. The reported high prevalence of this marker in 
CRC (30-40%) has led to several trials which have recently evaluated the clinical activity of 
alkylating agents in the metastatic setting [10-13]. Collectively, these studies showed that 
clinical benefit could be achieved in up to 40% of heavily pre-treated patients [11-13]. 
Despite minor differences in response rates and progression-free survival (PFS), all the 
above studies reported that only a fraction of MGMT methylated cases derived clinical 
benefit from treatment with dacarbazine or TMZ. We hypothesize that the relatively poor 
specificity of MGMT status as a predictive marker of response to alkylating agents could 
be explained by an inaccurate assessment of methylation due to sampling issues, tumor 
heterogeneity or suboptimal detection methods.  
 
Here we implemented the detection of MGMT methylation through the methyl beads, 
emulsion, amplification, and magnetics protocol also known as Methyl-BEAMing assay 
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[14]. We validated the predictive prognostic value of MGMT methylation testing in two 
GBM cohorts. We tested whether this technique could improve the assessment of MGMT 
methylation and the selection of CRC patients with higher probability of response to 
alkylating agents. We then compared it to commonly used methods, including Methylation 
Specific PCR [MSP] [15] and Bisulfite Pyrosequencing [Bs-Pyrosequencing] [16]. Finally, 
we evaluated the ability of the Methyl-BEAMing assay to detect tumor methylation status 
directly from plasma samples of CRC patients to evaluate the feasibility of patient selection 
for treatment via a blood test. 
 
Material and Methods 
Patients and sample preparation 
A first GBM training-set included tissue samples from 98 patients who had undergone 
brain surgery at the Academic Medical Center in Amsterdam, between 1988 and 2006 [17]. 
A second GBM validation-set consisted of 66 tissue samples from patients with newly-
diagnosed GBM, who had surgery and chemoradiation (radiotherapy and concomitant 
TMZ, followed by six monthly cycles of adjuvant TMZ) with a follow-up of at least two years 
at the VU University Medical Center in Amsterdam. The DETECT-01 trial composed the 
CRC training-set, in which 68 patients with chemorefractory metastatic CRC (mCRC) were 
treated with dacarbazine [11]. The validation-set consisted of 23 samples from a phase II 
trial, in which 32 patients with chemorefractory metastatic CRC (mCRC) were treated with 
TMZ [13]. Further details about the cohorts and the sample preparation can be found in 
Data S1. The studies followed the Declaration of Helsinki and were approved by local 
ethics committees. 
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MGMT methylation assays 
MGMT methylation was retrospectively assessed in tissue sample DNA using MSP, Bs-
pyrosequencing and Methyl-BEAMing. Analyses were performed in a blinded fashion 
without prior knowledge of MGMT methylation status. Cell-free circulating DNA (cfDNA) 
(cfDNA) was assessed by Methyl-BEAMing. All the assays targeted CpGs within the 
differentially methylated region number 2 previously associated with TMZ response [18]. 
Detailed protocols are provided in Data S1. Sensitivity, reproducibility and specificity of 
MGMT Methyl-BEAMing assays can be found in Data S2.  
 
Quality control of cfDNA 
Three different assays were used to evaluate the presence of cfDNA from tumor origin 
(circulating tumor DNA, ctDNA): Methyl-BEAMing assays specific for SEPT9 and VIM 
methylation (markers highly prevalent in mCRC) and Droplet Digital™ PCR assays for the 
KRAS mutational status for samples known to be mutated in the tumor tissue (Data S1). 
 
Statistical Analyses 
Survival analyses and kappa statistics were performed using Prism 6.01 for Windows 
(GraphPad Software). Differences in survival were tested by the log-rank test (Mantel-Cox). 
ROC analyses were performed with R bioconductor using the pROC package [19]. 
Hazard-Ratios were expressed using the log-rank test. All expressed p-values were 
calculated with two-tailed tests and were considered significant when p<0.05.  
 
Results 
Prognostic and predictive value of MGMT methylation in GBM 
MGMT methylation is a well-known prognostic marker in GBM [8]. In order to establish the 
prognostic value of MGMT status assessed by Methyl-BEAMing, we employed tissue 
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samples from a cohort of 98 patients with GBM diagnosed before TMZ was introduced as 
component of standard treatment for these tumors [17]. Methyl-BEAMing was compared 
with two established techniques, namely MSP and Bs-Pyrosequencing. For each method, 
ROC analysis was performed to evaluate the threshold best fitting the overall survival (OS) 
at 1 year (Data S3A-C). Methylation classification for the three methods concurred in most 
of the cases with the best agreement between Bs-Pyrosequencing and Methyl-BEAMing 
(86.7%) (Data S3D). All three methods identified a methylated subgroup of patients with 
better OS (p<0.05 for all methods); however quantitative techniques (Bs-Pyrosequencing, 
Methyl-BEAMing) displayed a better specificity. Then, only quantitative methods were 
assessed in a validation cohort of 66 GBM treated with TMZ. Methylation ranges, status, 
and association with survival for both techniques are summarized in Table S1 and Data 
S3E-G. OS and PFS according to methylation status by both techniques are shown in 
Figure 1 and demonstrated better identification of long term responders with Methyl-
BEAMing. Comparison of hazard-ratios (Data S3H), showed a better stratification of the 
population with good prognosis and response to TMZ by Methyl-BEAMing. 
 
Prognostic and predictive value of MGMT methylation in mCRC 
The DETECT-01 study evaluated dacarbazine treatment for mCRC patients after failure of 
standard therapies. The original report determined MGMT methylation status via MSP and 
found that 44% of patients in the methylated subgroup achieved disease control as 
assessed by radiological methods, although no improvement in PFS was observed [11]. 
Archived FFPE tumor samples were available for 61 of the 68 patients originally enrolled in 
the trial. MGMT assessment was successful in 56 cases (91.8%) by MSP, 59 (96.7%) by 
Bs-Pyrosequencing and in all 61 cases by Methyl-BEAMing. Methylation values were 
normalized for 60 cases for which tumor content was available (Data S1). All techniques 
showed a bimodal distribution with similar range (Data S4A-B). MGMT methylation ranges, 
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status and association with survival are in Table S1. For each method ROC analysis was 
performed to evaluate the threshold best fitting the PFS at 12 weeks (Data S4C). When 
these cut-off values were applied, the number of cases classified as methylated by MSP, 
Bs-Pyrosequencing and Methyl-BEAMing was 18 (30%), 10 (17%) and 12 (20%), 
respectively. This resulted in 92% concordance between Bs-Pyrosequencing and Methyl-
BEAMing, and 77% and 72% agreement between MSP and Methyl-BEAMing or Bs-
Pyrosequencing respectively (Data S4D). No association with OS was observed with any 
of the techniques (Data S4E), suggesting that MGMT status might lack prognostic value in 
mCRC. 
Response to dacarbazine was evaluated using RECIST criteria. Among the 61 available 
cases, nine patients showed disease control (two responders and seven individuals with 
stable disease; Data S4). MSP classified 18 cases as methylated, which included seven of 
the nine patients achieving clinical benefit, thereby displaying a positive predictive value 
(PPV) of 0.39 and a negative predictive value (NPV) of 0.88 (Figure 2A). Bs-
Pyrosequencing achieved a PPV of 0.8 and NPV of 0.89, by classifying a total of 10 cases 
as methylated, of which eight patients with disease control (Figure 2B). Methyl-BEAMing 
identified 12 tumors as methylated, of which eight (67%) were from patients with clinical 
benefit (Figure 2C), resulting in a PPV of 0.67 and a NPV of 0.89. 
Next, Bs-Pyrosequencing and Methyl-BEAMing were assessed in a validation cohort of 23 
samples from mCRC patients treated with TMZ using the above identified cut-off values. 
Methyl-BEAMing was successful in 21 cases (91%) and identified 8 tumors as methylated, 
of which 4 (50%) were from patients with clinical benefit (all partial responders) (Data S4G-
H), achieving a PPV of 0.5 and a NPV of 0.67. Methyl-BEAMing methylated subgroup also 
showed a trend for improved PFS. Bs-Pyrosequencing failed in 15 cases (65%) preventing 
further analyses.  
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Analysis of cfDNA in plasma from mCRC Patients  
MGMT methylation of cfDNA was only assessed by Methyl-BEAMing assay. Evaluation 
was successful in all 49 available samples. MGMT ranges, status and association with 
survival are shown in Table S1. ROC analysis was performed to define the best threshold 
in cfDNA (Data S4C). Thirty-eight unmethylated cases (75.6%) were identified. To verify 
the presence of DNA from tumor origin (circulating tumor DNA, ctDNA), we assessed 
KRAS mutational status for the 20 cases with known G12 or G13 mutation in the 
corresponding tumor tissue, as well as SEPT9 and VIM methylation in all samples. 
Methylated SEPT9 and VIM are two early markers of detection of intestinal disease 
reported with over 85% prevalence in mCRC [14, 20]. Six samples were considered as low 
ctDNA (four KRAS mutated and two wild type cases) since they displayed neither KRAS 
mutation nor methylation in SEPT9 or VIM in plasma (Figure 1D) despite showing these 
alterations in the corresponding tissue (data not shown).  
 
Out of the 49 available plasma samples only 43 had remaining matched tissue that could 
be assessed for tumor content and MGMT methylation. Concordance was seen in 37 
cases (86.1%) (six methylated and 31 unmethylated cases; Figure 1E; Data S4I). 
Correlation between the MGMT methylation status in tissue and plasma samples indicates 
that most of the methylated alleles present in the tissue were released in the blood 
(Spearman correlation= 0.53, p=0.0003). 
 
MGMT methylated status in cfDNA was also associated with a significantly improved 
median PFS (2.1 months vs. 1.8 months for unmethylated group, p=0.008, Table S1, Data 
S4E). Among the available plasma samples, seven were obtained from patients with 
clinical benefit from dacarbazine treatment. MGMT methylated status was observed in 11 
(22%) plasma and identified five of the seven patients achieving clinical benefit (Figure 1F, 
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Data S4F). Among the two unmethylated cases with clinical benefit, one did not have 
remaining tissue sample DNA and the second was considered as low ctDNA.  
 
Discussion 
MGMT methylation has been previously identified as a prognostic and predictive marker in 
GBM [2-5]. However its specificity for response prediction in GBM and other cancer types 
remains controversial. MGMT methylation status is usually evaluated by MSP or Bs-
Pyrosequencing [15, 16]. Notably, recent phase II clinical trials in mCRC with alkylating 
agent therapies relied on MSP evaluation of MGMT [11-13] for patient selection or 
evaluation of response prediction. These studies demonstrated that up to 40% of heavily 
pretreated mCRC patients achieved some clinical benefit, indicating that drug repositioning 
could be helpful in this setting upon improved patient selection [21]. Here, we describe the 
use of Methyl-BEAMing, a highly sensitive and reproducible technique for the detection of 
MGMT methylation in tissue and plasma samples derived from cancer patients.  
 
Prognostic significance of MGMT methylated status assessed by Methyl-BEAMing in GBM 
was improved compared to MSP or Bs-Pyrosequencing. Predictive value of MGMT 
methylated status for response to TMZ was also observed with a better stratification using 
Methyl-BEAMing compared to Bs-Pyrosequencing. Plasma samples were not available for 
the GBM patients, thereby preventing us from assessing the potential role of liquid biopsy 
in this setting. While the blood brain barrier may limit the amount of cfDNA in patients 
affected by CNS malignancies [22], it has been shown that real-time PCR can be used to 
detect MGMT methylation in the plasma of glioblastoma patients receiving TMZ [23]. 
Further studies are therefore warranted to clarify the role of liquid biopsy in GBM [24].  
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Our study retrospectively assessed two mCRC cohorts for which DNA was extracted from 
FFPE tissue. The three methods successfully evaluated most of the CRC samples in the 
first training-set yet with a better performance obtained with Methyl-BEAMing in terms of 
dynamic range. Both mCRC patient cohorts were enrolled in clinical trials with alkylating 
agents thus allowing the assessment of MGMT methylation as a predictive biomarker. 
Both Methyl-BEAMing and Bs-Pyrosequencing outperformed MSP in the CRC training-set 
strongly indicating that quantitative methods are needed to assess methylation markers in 
tissue. However, Bs-Pyrosequencing failed to reliably assess MGMT promoter methylation 
status in most of the samples of the validation cohort for which only limited amount of DNA 
was available. Consequently, although Bs-Pyrosequencing provides a robust quantification, 
its requirement for DNA with high quality and quantity could limit its use for specific sample 
types such as FFPE biopsies or cfDNA. 
 
Of interest, a number of GBM cases showed intra-locus heterogeneity by Bs-
Pyrosequencing (also described by Bady et al. using a methylation microarray platform 
[18]); while this pattern was rarely seen in the mCRC samples (Data S4I). As the current 
Bs-Pyrosequencing is the average of the six evaluated CpG sites, its accuracy might suffer 
from the heterogenous profiles observed in GBM as well as by incomplete bisulfite 
conversion. Therefore we hypothesize that this could explain the discrepancy of 
performance between Bs-Pyrosequencing and Methyl-BEAMing in the two tissue types. 
 
It is also possible that MGMT methylation heterogeneity exists among individual tumor 
cells and that MGMT immunostaining could be used in combination with methylation 
based methods to better refine selection of patients [25]. However, so far, observer 
variability and lack of association with patient survival has hampered the use of 
immunohistochemistry as clinical biomarker in GBM [26, 27]. Studies that have addressed 
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the role of MGMT immunostaining as predictive biomarker of response in CRC are limited 
to case reports [10] and further investigations are needed in larger cohorts. 
  
Plasma samples were only available for patients in the mCRC training cohort. We 
successfully assessed all cases via Methyl-BEAMing demonstrating high efficiency even 
with samples of poor quality and limited quantity. Reliability of the results was limited in a 
few instances by the observation that cfDNA samples are not only composed of DNA of 
tumor origin [22]. Therefore we evaluated SEPT9 and VIM methylation, and KRAS 
mutation (when the tissue demonstrated an alteration) in cfDNA. Six samples out of 49 
showed the absence of all these markers, strongly suggesting the absence of ctDNA. Use 
of higher volume of plasma or exploitation of micro-vesicles, such as exosomes [28] could 
potentially solve this issue. Discrepancies between the plasma and tissue could be mainly 
explained by the low abundance of ctDNA. In the remaining cases, we hypothesized that 
the tumor might have evolved between the time of diagnosis (tissue collection) and the 
treatment (plasma collection) since this period could have been longer than 10 years. An 
ongoing study including fresh biopsies is being performed to investigate whether and to 
what extent there is change of MGMT methylated status over time [29]. Nevertheless, the 
present comparison of plasma and tissue samples showed that cfDNA could be used as a 
good surrogate to tissue biopsies when the tumor load is controlled and normalized. To 
achieve this aim, optimization of house-keeping genes highly methylated in cancer and 
poorly methylated in blood is required. Development of such markers for each cancer type 
might be required and would enable a better use of alkylating agents across several 
malignancies. 
 
In conclusion, regardless of the DNA origin (FFPE tissue or plasma) assessment of MGMT 
methylated status by Methyl-BEAMing selected a population highly enriched in patients 
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showing clinical benefit with dacarbazine or TMZ treatment. Our study therefore supports 
the clinical implementation of quantitative methods to measure MGMT methylation and 
improve selection of patients who could benefit from alkylating agent-based therapies.  
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Figure 1: Overall (OS) and Progression Free Survival (PFS) of the GBM validation cohort 
by (A) Bs-pyrosequencing, and (B) Methyl-BEAMing. Methylated subgroup is in blue, 
Unmethylated in orange and censored cases are represented by circles. 
 
Figure 2A: Predictive value of MGMT methylation status by MSP in mCRC tissue. 
Waterfall plot indicates response to dacarbazine. 
Figure 2B: Predictive value of MGMT methylation status by Bs-Pyrosequencing in mCRC 
tissue. Waterfall plot indicates response to dacarbazine. 
Figure 2C: Predictive value of MGMT methylation status by Methyl-BEAMing in mCRC 
tissue. Waterfall plot indicates response to dacarbazine. 
Figure 2D: Distribution of methylation (MGMT, SEPT9, VIM) and mutational (KRAS) 
values in cfDNA. Individual samples were ranked according to average of SEPT9 + VIM + 
KRAS. Grey area corresponds to cases in which no markers were detectable (<1%) and 
hence were considered to contain very low ctDNA. Threshold for MGMT methylated status 
is plotted as a dot line.  
Figure 2E: Scatter plot of methylation values in tissue and plasma with Spearman 
correlation according to methylated status. Threshold for each type of tissue is indicated 
by a dot line. 
Figure 2F: Predictive value of MGMT methylation status by Methyl-BEAMing in mCRC 
plasma. Waterfall plot indicates response to dacarbazine. 
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